Involving A Micro-organism Or Cell Membrane Bound Antigen Or Cell Membrane Bound Receptor Or Cell Membrane Bound Antibody Or Microbial Lysate Patents (Class 435/7.2)
  • Patent number: 10214584
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 26, 2019
    Assignee: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki Satofuka, Kensuke Ohse, Shigeki Mukobata, Hirotada Akiyama, Masaya Ohtsu, Yoko Okabe, Yasufumi Murakami
  • Patent number: 10160978
    Abstract: The invention relates to mammalian cells comprising at least one prokaryotic two-component signaling (TCS) pathway comprised of an activator protein A, a response regulator (RR) protein B activated by said protein A, such activation leading to an activated RR protein B, and an output gene C operably linked to a promoter. Transcription from said promoter is activated by activated RR protein B, and the expression of output gene C defines at least a first state (0, no transcription) and a second state (1, detectable transcription). The invention further relates to logic gates designed from such cells, and methods for integrating a plurality of output signals based on the cells and logic gates of the invention.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: December 25, 2018
    Assignee: ETH ZURICH
    Inventors: Yaakov Benenson, Jonathan Hansen, Krishna Kumar Swaminathan
  • Patent number: 10145794
    Abstract: A cell information obtaining method comprises causing a plurality of fluorescent substances having different fluorescence wavelengths from each other to be bound to a test substance contained in a cell, applying light to the cell to cause fluorescences having different wavelengths and intensities to be generated from the plurality of fluorescent substances, and obtaining a first fluorescence information and a second fluorescence information on the basis of the generated fluorescences.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: December 4, 2018
    Assignee: SYSMEX CORPORATION
    Inventor: Keiko Yoshikawa
  • Patent number: 10137150
    Abstract: Structures based on graphene-related materials, methods for their preparation, and methods for their use are disclosed. These structures can be utilized for manipulating the cell transmembrane potential in various biomedical applications.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: November 27, 2018
    Inventor: Elena Molokanova
  • Patent number: 10139404
    Abstract: The present invention relates to the use of a control marker for implementing analysis methods on spots, in particular in the context of multiplex analyses. The present invention thus relates to solid supports containing said control marker, their preparation method and their use in analysis methods. The present invention makes it possible to verify the presence, location and/or integrity of the spots at the end of the analysis method, and thus to secure the obtained results while guaranteeing that the yielded result indeed results from a present, intact and localized spot.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: November 27, 2018
    Assignee: BIO-RAD EUROPE GMBH
    Inventors: Agnes Roseline Claude Pouzet, Vincent Doury, Laurent Emmanuel Fournier, Christophe Rene Roger Vedrine
  • Patent number: 10130593
    Abstract: This disclosure concerns the discovery of the use of fenoterol analogs for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analog to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: November 20, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Irving William Wainer, Michel Bernier, Rajib Kumar Paul
  • Patent number: 10106595
    Abstract: The present invention relates to fusion proteins for the expression of G-protein coupled receptor proteins (GPCR) with the fusion partners, as inserted fragments, from mammalian cells. The fusion partners are from a fragment of APJ protein (“the APJ protein fragment”) or a fragment with homology of more than 90% similarity to the APJ protein fragment; or a fragment of RGS16 protein (the “RGS16 protein fragment”) or a fragment with homology of more than 90% similarity to the RGS16 protein fragment; or the fragment of DNJ protein (the “DNJ protein fragment”) or a fragment with homology of more than 90% similarity to DNJ protein fragment. The fusion expression of GPCR with the above mentioned fusion partners can improve the protein yield and stability when purified from cells. Therefore, these fusion protein partners can be widely used for the study of GPCR proteins.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 23, 2018
    Assignee: VIVA BIOTECH (SHANGHAI) LTD.
    Inventors: Jianhua Cai, Jian Shen, Fan Jiang, Na Li, Wentao Wei, Xiuhong Zeng, Xiaoyan Su, Min Han, Delin Ren, Chen Mao
  • Patent number: 10100128
    Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 16, 2018
    Assignee: AROCELL AB
    Inventor: Staffan Eriksson
  • Patent number: 10087208
    Abstract: Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 2, 2018
    Assignee: AM CHEMICALS LLC
    Inventors: Andrei Pavel Guzaev, Vladimir Y. Vvedenskiy
  • Patent number: 10078087
    Abstract: This invention relates to electrophysiological assays that measure sodium conductance activity of a delta human epithelial sodium channel (ENaC) in the presence and absence of delta hENaC enhancers. Also, the invention generally relates to assays for identifying compounds that enhance the activity of delta hENaC, especially in an oocyte expression system. These compounds have potential application in modulating (enhancing) salty taste perception.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: September 18, 2018
    Assignee: SENOMYX, INC.
    Inventors: Bryan Moyer, Min Lu, Fernando Echeverri, Hong Chang
  • Patent number: 9994605
    Abstract: The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: June 12, 2018
    Assignee: UNIVERSITAET BASEL
    Inventors: Beat Ernst, Ruben Herrendorff, Andreas Steck, Fan Yang
  • Patent number: 9982260
    Abstract: This invention relates, e.g., to a method for enhancing exon skipping in a pre-mRNA of interest, comprising contacting the pre-mRNA with an effective amount of a compound such as, for example, Perphenazine, Flupentixol DiHCl, Zuclopenthixol or Corynanthine HCl, or a compound which shares a similar 2-D structure and activity level with one of these compounds, or a pharmaceutically acceptable salt, hydrate, solvate, or isomer of the compound, and, optionally, with an antisense oligonucleotide that is specific for a splicing sequence in the pre-mRNA Methods for treating Duchenne muscular dystrophy (DMD) are disclosed.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: May 29, 2018
    Assignee: The Regents of The University of California
    Inventors: Genevieve C. Kendall, Stanley F. Nelson, M. Carrie Miceli
  • Patent number: 9970848
    Abstract: The invention relates to providing a method for more conveniently evaluating stratum corneum condition. A stratum corneum sheet is contacted with a solution of a water-soluble dye, and the staining intensity or fluorescence intensity is measured to allow convenient evaluation of the stratum corneum condition. There is further provided a method for evaluating the ameliorating effect of a cosmetic or cosmetic treatment on the stratum corneum, by implementing the method for evaluating stratum corneum condition using a water-soluble dye according to the invention.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: May 15, 2018
    Assignee: Shiseido Company, Ltd.
    Inventors: Eiichiro Yagi, Ichiro Iwai
  • Patent number: 9968935
    Abstract: The present invention relates to the field of molecular diagnostics. In particular, the present invention provided improved substrates and methods of using liquid crystals and other biophotonically based assays for quantitating the amount of an analyte in a sample. The present invention also provides materials and methods for detecting non-specific binding of an analyte to a substrate by using a liquid crystal or other biophotonically based assay formats.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: May 15, 2018
    Assignee: Platypus Technologies, LLC
    Inventors: Nicholas Abbott, Christopher Murphy, Barbara Israel, Josh Sotos, Doug Hansmann, Renee Herber, Joseph Burkholder, Keren Hulkower, Michael Bonds
  • Patent number: 9952202
    Abstract: The present invention relates to methods and assays for identifying agents useful in the treatment of fibrotic diseases, in particular diseases related to fibroblast migration and differentiation. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of fibrotic disease. The invention further provides in vitro methods for inhibition of fibroblast migration and differentiation.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 24, 2018
    Assignee: GALAPAGOS NV
    Inventors: Richard Antonius Jozef Janssen, Annemarie Nicolete Lekkerkerker, Jamil Aarbiou, Krista Ouwehand
  • Patent number: 9939587
    Abstract: An on-chip optical filter having Fabri-Perot resonators and a spectrometer may include a first sub-wavelength grating (SWG) reflecting layer and a second SWG reflecting layer facing each other. A plurality of Fabri-Perot resonators are formed by the first SWG reflecting layer and the second SWG reflecting layer facing each other. Each of the Fabri-Perot resonators may transmit light corresponding to a resonance wavelength of the Fabri-Perot resonator. The resonance wavelengths of the Fabri-Perot resonators may be determined according to duty cycles of grating patterns.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 10, 2018
    Assignees: SAMSUNG ELECTRONICS CO., LTD., CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Seunghoon Han, Yu Horie, Andrei Faraon, Amir Arbabi
  • Patent number: 9925537
    Abstract: A microfluidic device is configured to analyze a sample of biological material. The microfluidic device includes a fluid guide structure constructed in order to divide a sample introduced into the microfluidic device into a plurality of subquantities. The microfluidic device further includes a plurality of reaction chambers each of which is fluidically connected to the fluid guide structure. Each of the reaction chambers has a filter configured to filter out target cells from the sample, and each of the reaction chambers is constructed to receive a sample subquantity. In each of the reaction chambers, a result of a reaction between a target-cell-specific active substance that is different for each of the reaction chambers and the target cells of the sample subquantity that is taken up is acquirable.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Robert Bosch GmbH
    Inventor: Jochen Hoffmann
  • Patent number: 9903867
    Abstract: The present invention provides assays and methods for predicting the survival of a subject having colorectal cancer (CRC), thereby determining whether the subject will have a good prognosis or poor prognosis. The present invention also provides assays and methods for predicting therapeutic efficacy and/or response to anti-cancer therapeutics in a subject having CRC, thereby selecting a therapeutic regimen to which the subject is likely to be responsive.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 27, 2018
    Assignee: Nestec S.A.
    Inventors: Phillip Kim, Anjali Jain, Sharat Singh
  • Patent number: 9897848
    Abstract: The invention provides a manufacturing method of color resist layer to manufacture the color resist layer by micro transfer printing (MTP), comprising forming a color resist thin film on a first substrate, using a MTP transfer stamp to adsorb a part of the color resist thin film to the plurality of protrusions of the MTP transfer stamp, and transferring the color resist thin film adsorbed by the plurality of protrusions of the MTP transfer stamp to the second substrate to form the color resist layer on the second substrate. The method uses the protrusions of the MTP transfer stamp to form the pattern to control the pattern of the color resist layer instead of exposure and development. No color resist material is wasted, the cost is reduced and the process is simple and widely applicable.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 20, 2018
    Assignee: SHENZHEN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD.
    Inventor: Lixuan Chen
  • Patent number: 9880152
    Abstract: Described herein are compositions, methods and/or kits for determining the likelihood of a pregnant subject delivering at term, or developing a disorder associated with pregnancy. These compositions, methods and/or kits feature the measurement of the chemotactic activity of peripheral leukocytes, the measurement of ccl2 mRNA expression or the measurement of Fp or Otr protein expression.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: January 30, 2018
    Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Nardhy Gomez-Lopez, David Olson
  • Patent number: 9862924
    Abstract: Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: January 9, 2018
    Assignee: Wake Forest University Health Sciences
    Inventor: Khalil Bitar
  • Patent number: 9856254
    Abstract: Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: January 2, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Kyle J. Lindstrom, Bryon A. Merrill, Chad A. Haraldson, Michael J. Rice, Tushar A. Kshirsagar, Philip D. Heppner, Joshua R. Wurst, Shri Niwas, Sarah J. Slania
  • Patent number: 9856535
    Abstract: A system and method for isolating cells, comprising: a substrate having a broad surface; an array comprising a set of wells defined at the broad surface of the substrate, each well including: a base surface, an open surface directly opposing the base surface, defined at the broad surface of the substrate, and configured to receive one of a single cell and a single cluster of cells from a direction perpendicular to the broad surface of the substrate, and a set of channels that fluidly couple each well to at least one adjacent well; wherein the set of wells includes an interior subset and an exterior subset fluidly coupled to and surrounding the interior subset by way of the set of channels; and a fluid delivery module surrounding the array and fluidly coupled to each well in the set of wells.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: January 2, 2018
    Assignee: DeNovo Sciences, Inc.
    Inventors: Kalyan Handique, Priyadarshini Gogoi, Yi Zhou, Saedeh Sepehri, Christopher Siemer
  • Patent number: 9828625
    Abstract: Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 28, 2017
    Assignee: Phage Diagnostics, Inc.
    Inventors: Michael Sandor Koeris, Julie Thomason, Michael Cappillino, Robert Patrick Shivers, Daniel Robert Brownell, Jayson L. Bowers, Timothy Kuan Ta Lu, Edyta Krzymanska-Olejnik
  • Patent number: 9770478
    Abstract: The invention relates to a novel use of the Chinese herb Glycyrrhiza inflata in treatment of neurodegenerative disorders. Particularly, the invention relates to the use of ammonium glycyrrhizinate and licochalcone A in targeting polyQ-mediated spinocerebellar ataxia.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: September 26, 2017
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Guey-Jen Lee-Chen, Chiung-Mei Chen
  • Patent number: 9771554
    Abstract: A device for assembling aggregations of adherent cells includes a gripper moveable within an assembly vessel that fixes aggregations of adherent cells at a membrane of the gripper and, by movement of the gripper, assembles aggregations of cells on a separate membrane within the vessel, thereby creating a three-dimensional assembly of aggregations of cells that fuse and can be employed in surgical procedures as a unitary tissue of adherent cells. The aggregations of cells, as assembled, can assume three-dimensional configurations distinct from any one of the component aggregations of cells assembled.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: September 26, 2017
    Assignees: Brown University, Rhode Island Hospital
    Inventors: Jeffrey R. Morgan, Andrew Blakely, John Murphy, Anubhav Tripathi, William Patterson
  • Patent number: 9754383
    Abstract: The invention concerns automated methods for assessing tissue morphometry in digital images of tissue sections derived from small intestine biopsy samples from patients submitted for evaluation of celiac disease. The methods generally involve digital image analysis of tissue section images, and specifically involve post-processing each image to produce a binary mask capturing the tissue area footprint on the glass slide. Virtual stereology probes are placed on each image and assessed to estimate the ratio of the surface area to volume of the tissue specimen. The surface area to volume ratio is used to diagnose celiac disease and make inferences about the severity of celiac disease in those individuals with a positive diagnosis of celiac disease.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: September 5, 2017
    Assignee: FLAGSHIP BIOSCIENCES, INC.
    Inventors: Erik Hagendorn, Steven Potts, Nathan T. Martin
  • Patent number: 9726669
    Abstract: The present invention provides compositions and methods for detecting the expression and/or activation states of components of signal transduction pathways in cells such as tumor cells. Information on the expression and/or activation states of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: August 8, 2017
    Assignee: PIERIAN HOLDINGS, INC.
    Inventors: Phillip Kim, Xinjun Liu, Richard Kirkland, Tani Lee, Belen Ybarrondo, Sharat Singh
  • Patent number: 9719982
    Abstract: The present invention provides high throughput assays for identifying compounds that modulate a contractile function, as well as devices suitable for use in these assays.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: August 1, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Kevin Kit Parker, Adam W. Feinberg, Patrick W. Alford, Anna Grosberg, Mark Daniel Brigham, Josue A. Goss
  • Patent number: 9718887
    Abstract: The present disclosure relates to the prevention and/or treatment of metastatic cancer. Certain example embodiments of the present disclosure provide a method for preventing and/or treating a metastatic cancer in a subject. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of a chemokine receptor CCX-CKR.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 1, 2017
    Assignees: Adelaide Research & Innovation PTY LTD, Peter Maccallum Cancer Institute
    Inventors: Shaun Reuss Mccoll, Ian Comerford, Yuka Harata-Lee, Mark Smyth
  • Patent number: 9709500
    Abstract: The invention relates to a method for determining the presence and/or amount of viable cells in a liquid sample. The method includes (a) labeling with a fluorescent label viable cells remaining on a porous membrane after passing the liquid sample therethrough, (b) scanning a portion of the porous membrane by rotating the porous membrane relative to a detection system, and (c) determining the presence and/or quantity of viable cells captured by the membrane.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: July 18, 2017
    Assignees: Charles River Laboratories, Inc., ReaMetrix Inc.
    Inventors: Norman R. Wainwright, Bala S. Manian, Eric Stimpson, Brian J. Kolonia, Robert K. Kolonia
  • Patent number: 9709468
    Abstract: A sample preparation device includes: a filter member including a filter configured to separate cells being an analysis target from other components in a sample; a first receptacle and a second receptacle configured to be connected to each other via the filter; a third receptacle capable of holding the sample therein; a negative pressure section configured to apply a negative pressure into the second receptacle, thereby to move the sample in the third receptacle toward the filter via the first receptacle, and thereby to move components other than the analysis target into the second receptacle via the filter; and a positive pressure section configured to apply a positive pressure from the second receptacle side to the filter to which cells being the analysis target are attached.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: July 18, 2017
    Assignee: SYSMEX CORPORATION
    Inventors: Ryuichiro Ebi, Koki Tajima, Toshikuni Suganuma
  • Patent number: 9700637
    Abstract: Disclosed are compounds and methods useful in the detection of e.g., Zn2+, in vitro and in vivo. The compounds include amino acids and peptides functionalized with a moiety that binds, e.g., Zn2+. Importantly, the compounds do not exhibit substantial fluorescence in the absence of zinc.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: July 11, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Robert J. Radford, Stephen J. Lippard, Wen Chyan
  • Patent number: 9689873
    Abstract: The present invention provides a method using immunoassay devices to differentiate infection with HIV-2 from infection with both HIV-1 and HIV-2 in a subject.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: June 27, 2017
    Assignee: BIO-RAD INNOVATIONS
    Inventor: Pierre Chaumat
  • Patent number: 9684011
    Abstract: A method for assessing turbulence parameters of a medium comprises the following steps: the illumination, by a laser beam being propagated in said medium, of a film of photochromic organic material that can comprise molecules of azobenzene, or of spyropyrane, or of stilbene, or of coumarin, or of fulgide, said illumination creating a surface grating in said film comprising scratches, the deformations of which are a function of the turbulence parameters; a step of acquisition of images comprising individual areas of structures linked to said scratches, more or less reduced and representative of the turbulence parameters of said medium; a step of processing of said images that makes it possible to assess the turbulence parameters of said medium. A device is also provided.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 20, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ANGERS, WROCLAW UNIVERSITY OF TECHNOLOGY
    Inventor: Regis Barille
  • Patent number: 9677109
    Abstract: This disclosure is related to systems and methods for rapid determination of microorganism growth and antimicrobial agent susceptibility and/or resistance.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 13, 2017
    Assignee: Accelerate Diagnostics, Inc.
    Inventors: Alena Shamsheyeva, David C. Howson, Steven W. Metzger
  • Patent number: 9678073
    Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: June 13, 2017
    Assignee: Beckman Coulter, Inc.
    Inventors: Fabrice Malergue, Andreas Van Agthoven
  • Patent number: 9671395
    Abstract: The invention generally relates to conducting an assay on a sample that isolates a pathogen from the sample and allows for analysis of the pathogen with minimal (i.e., at most 24 hrs of culturing) or no culturing of the pathogen. In certain embodiments, the invention provides methods for identifying a pathogen from a sample that involve obtaining a sample including a pathogen, conducting an assay that isolates the pathogen from the sample, culturing the isolated pathogen for at most about 24 hrs, and analyzing the pathogen.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: June 6, 2017
    Assignee: DNAE Group Holdings Limited
    Inventors: Sergey A. Dryga, Lisa-Jo Ann Clarizia, Eddie W. Adams, Victor C. Esch
  • Patent number: 9664663
    Abstract: A method of testing water is described which includes the steps of taking a water sample to be tested, diluting the water sample to create a test water sample, applying a reagent to the water sample, heating the test water sample for a predetermined period, and using the color of the test water sample to provide an indication of the water quality.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: May 30, 2017
    Assignee: University of Plymouth
    Inventors: Simon Jackson, Anas Akram Sattar, Graham Bradley
  • Patent number: 9624284
    Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: April 18, 2017
    Assignee: Immunotope, Inc.
    Inventor: Ramila Philip
  • Patent number: 9624524
    Abstract: The application discloses methods, materials, and compositions for the labeling of molecules, for example, proteins, in living cells or in subcellular compartments of living cells. In particular, the application relates to proteomic analysis methods; materials and compositions and means based on direct tagging of unknown proteins with tagging enzymes (such as biotin ligase or a peroxidase) within the vicinity of a tagging substrate (such as a tyramide) within living cells, with optional targeting to specific subcellular locations by expression of genetic constructs.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 18, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Alice Y. Ting, Jeffrey Daniel Martell, Hyun-Woo Rhee, Peng Zou
  • Patent number: 9605079
    Abstract: The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: March 28, 2017
    Assignee: MEDVET SCIENCE PTY LTD.
    Inventors: Simon Barry, Doreen Krumbiegel, Nicola Ga-Ling Eastaff-Leung, Ian Cameron Nicholson, Heddy Zola
  • Patent number: 9562839
    Abstract: The present invention describes a tubular scoop that may be utilized with various assemblies for sampling fluid in a pipeline. The scoop includes a bend with a bend radius that is from two to four times the diameter of the scoop. The scoop defines a scoop face that is parallel to an axis of the tubular of the scoop. The scoop is mounted with a threaded connection that seals around the tubular. An additional seal comprises a compression nut that allows orientation of the scoop within the pipeline whereupon the scoop orientation is fixed by tightening the compression nut.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: February 7, 2017
    Inventor: Martin Atchison
  • Patent number: 9551719
    Abstract: Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 24, 2017
    Assignee: EXPRESSION PATHOLOGY, INC.
    Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil, Wei-Li Liao
  • Patent number: 9546397
    Abstract: The present invention provides an aptamer or pool of aptamers (nucleic acid sequences) that bind(s) to a target molecule on the surface, accessible from the surface or inside of a mammalian sperm cell and a method for producing the aptamers. The method comprises contacting a collection of different nucleic acid molecules with the target molecule under conditions favorable for binding between at least one of the nucleic acid molecules and the target molecule, to form at least one complex comprising the nucleic acid molecule bound to the target molecule, wherein each of the nucleic acid molecules comprises at least one segment of randomized nucleotide sequences. The complexes are then separated from the unbound nucleic acid molecules and unbound target molecules, and the bound nucleic acid molecule is recovered from the separated complex. The aptamers are used to separate sperm cells based upon sperm cell qualities, such as whether the cells contain X chromosomes or Y chromosomes.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: January 17, 2017
    Assignee: Biocern Inc.
    Inventors: David Oksenberg, Sergey Krylov, Michael Musheev
  • Patent number: 9541004
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: January 10, 2017
    Assignees: NOVARTIS AG, XOMA TECHNOLOGY LTD.
    Inventors: Linda Masat, Jeff Hsu
  • Patent number: 9541542
    Abstract: Disclosed is a method of detecting filarial larvae in blood. The method comprises preparing a measurement sample from a blood sample collected from an animal; flowing the prepared measurement sample through a flow cell; irradiating light on the measurement sample flowing through the flow cell; detecting light given off from the irradiated measurement sample; and detecting filarial larvae contained in the measurement sample based on characteristic parameter of the detected light.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: January 10, 2017
    Assignee: SYSMEX CORPORATION
    Inventors: Seiichiro Tsuchiya, Toshihiro Mizukami, Hideki Hirayama, Noriaki Nakajima, Ken Nishikawa
  • Patent number: 9534049
    Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: January 3, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Greg Elson, Olivier Leger
  • Patent number: 9534035
    Abstract: Cell lines that stably express ENaC and methods for using those cell lines are disclosed herein. The invention includes cell lines that express various subunit combinations and various proteolyzed isoforms of ENaC and techniques for creating cell lines. The ENaC-expressing cell lines are highly sensitive, physiologically relevant and produce consistent results.
    Type: Grant
    Filed: January 25, 2009
    Date of Patent: January 3, 2017
    Assignee: CHROMOCELL CORPORATION
    Inventors: Kambiz Shekdar, Jessica Langer, Dennis Sawchuk
  • Patent number: RE46379
    Abstract: The present invention relates to a method of determining the presence of a retinoblastoma protein (Rb)-mediated cancerous or pre-cancerous condition in a sample of fixed cells that involves exposing the sample to an antibody that recognizes phosphorylation of serine on the retinoblastoma protein (pS-Rb), and identifying cells in the sample that are recognized by the antibody to pS-Rb, where the recognition of pS-Rb in the sample determines the presence of an Rb-mediated cancerous or pre-cancerous condition. The method also involves identifying the presence of specific cell cycle markers and positive and negative cell cycle regulators to assess the stage of disease progression in a cancer patient having an (Rb)-mediated cancer. The present invention also relates to methods of assessing the efficacy of cancer therapy for an Rb-mediated cancer, determining the mechanism of cell cycle progression in an Rb-mediated cancer, and identifying cells predisposed to developing an Rb-mediated cancerous condition.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: April 25, 2017
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Selina Chen-Kiang, Scott A. Ely, Maurizio DiLiberto